<DOC>
	<DOC>NCT00814307</DOC>
	<brief_summary>This Phase 3 study is intended to provide evidence of the efficacy and safety of CP 690,550 when dosed 5 mg and 10 mg twice a day as monotherapy in adult patients with moderate to severe Rheumatoid Arthritis. It is intended to confirm the benefits of CP-690,550 in improving signs and symptoms and physical function that were observed in the Phase 2 Rheumatoid Arthritis studies.</brief_summary>
	<brief_title>A Phase 3 Study Comparing 2 Doses of CP-690,550 vs. Placebo for Treatment of Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Tofacitinib</mesh_term>
	<criteria>The patient has a diagnosis of RA based upon the American College of Rheumatology (ACR) 1987 Revised Criteria. The patient has active disease at both Screening and Baseline, as defined by both: ≥6 joints tender or painful on motion; and ≥6 joints swollen; and fulfills 1 of the following 2 criteria at Screening: 1.ESR (Westergren method) &gt;28 mm in the local laboratory. 2. CRP &gt;7 mg/L in the central laboratory Patient had an inadequate response to at least one DMARD (traditional or biologic) due to lack of efficacy or toxicity. No evidence of active or latent or inadequately treated infection with Mycobacterium tuberculosis. Patient has washed out of all DMARDs other that antimalarials Blood dyscrasias including confirmed: 1. Hemoglobin &lt;9 g/dL or Hematocrit &lt;30%; 2. White blood cell count &lt;3.0 x 109/L; 3. Absolute neutrophil count &lt;1.2 x 109/L; 4. Platelet count &lt;100 x 109/L History of any other autoimmune rheumatic disease other than Sjogren's syndrome No malignancy or history of malignancy. History of infection requiring hospitalization, parenteral antimicrobial therapy, or as otherwise judged clinically significant by the investigator, within the 6 months prior to the first dose of study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Antirheumatic Agents Clinical Trial</keyword>
</DOC>